A CBD Anorexia Pilot’s BMI Signal Was Different From Symptom-Scale Evidence
A small anorexia nervosa trial found a statistically significant BMI interaction while several symptom-scale improvements remained nonsignificant. The results should not be compressed into a claim that CBD has established efficacy for eating-disorder recovery.
A short trial in a selected population
Thirty-two women with anorexia nervosa or atypical anorexia nervosa were assigned equally to CBD or placebo for 21 days. CBD was titrated weekly from 1.25 mg/kg twice daily to a maximum of 6.25 mg/kg twice daily.
The investigators assessed pharmacokinetics, liver function and eating-disorder, anxiety and depressive symptoms. This was human pilot research, not an inference based solely on cannabinoid biology or animal appetite studies.
Significance varied by endpoint
The analysis reported a small significant group-by-time interaction favoring CBD for BMI change (p = 0.046). Selected measures of shape concern and perceived loss of control over eating had comparatively large estimated effect sizes but did not reach statistical significance.
A large estimated effect in a small sample can carry substantial uncertainty. It is not equivalent to a confirmed treatment effect, and change in BMI alone does not establish recovery of the psychological and behavioral dimensions of an eating disorder.
Why replication is necessary
The study was short and limited to women, constraining generalization to other populations and sustained treatment. The authors also noted limitations in sample size and characterization of concurrent psychotherapy.
CBD exposure and tolerability observations help determine whether further trials are feasible. They do not establish long-term safety, relapse prevention or a treatment recommendation. The defensible interpretation is a preliminary BMI signal alongside unresolved symptom outcomes, requiring larger and longer controlled evaluation.
Related: Interpreting CBD treatment outcomes.
Primary research
Cannabidiol in Anorexia Nervosa: A Double‐Blind Randomized Placebo Controlled Pilot Study to Test Safety, Pharmacokinetics, and Symptom Change. The International Journal of Eating Disorders (2026).
